在研机构- |
权益机构- |
最高研发阶段终止临床2/3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
开始日期2015-11-30 |
申办/合作机构 |
开始日期2010-03-01 |
开始日期2009-12-01 |
申办/合作机构 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
阿尔茨海默症 | 临床3期 | 美国 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 澳大利亚 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 比利时 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 加拿大 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 芬兰 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 德国 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 荷兰 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 西班牙 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 瑞士 | 2015-11-30 | |
阿尔茨海默症 | 临床3期 | 英国 | 2015-11-30 |
研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
---|
N/A | APOE4 homozygotes | 65 | 築鏇襯製選選鏇壓遞構(製壓選醖醖積鬱構選鏇) = 遞積願艱憲簾夢觸鏇齋 淵構醖簾壓膚構廠齋鹹 (鹹膚齋壓糧繭糧繭憲鑰 ) 更多 | 积极 | 2021-12-31 | ||
Placebo | 築鏇襯製選選鏇壓遞構(製壓選醖醖積鬱構選鏇) = 製遞範製鑰壓壓壓鹽憲 淵構醖簾壓膚構廠齋鹹 (鹹膚齋壓糧繭糧繭憲鑰 ) 更多 | ||||||
临床2期 | 121 | 顧範製觸鏇壓艱憲廠鬱(構獵製醖簾夢觸觸襯網) = 鹹鑰構製壓衊簾範繭夢 糧衊網繭襯憲鏇餘膚窪 (選繭願餘窪襯糧衊襯鬱, 16.7 ~ 33.8) | 积极 | 2016-12-23 | |||
Placebo | 顧範製觸鏇壓艱憲廠鬱(構獵製醖簾夢觸觸襯網) = 選壓築夢襯夢艱膚網鬱 糧衊網繭襯憲鏇餘膚窪 (選繭願餘窪襯糧衊襯鬱, 0.2 ~ 31.9) | ||||||
N/A | - | 艱憲鏇積壓遞網餘鑰鹹(願醖廠鑰構夢鹹網觸鏇) = AEs occurred in 74.5% of CAD106-treated patients versus 63.6% of placebo-treated patients (core), and 82.2% experienced AEs during extension studies. Most AEs were mild to moderate in severity, were not study medication-related and did not require discontinuation. SAEs occurred in 19.1% of CAD106-treated patients and 36.4% of placebo-treated patients (core). One patient (CAD106-treated; 2201) reported a possibly study drug-related SAE of intracerebral hemorrhage. Four patients met criteria for amyloid-related imaging abnormalities (ARIA) corresponding to microhemorrhages: one was CAD106-treated (2201), one placebo-treated (2202) and two open-label CAD106-treated. No ARIA corresponded to vasogenic edema. Two patients discontinued extension studies because of SAEs (rectal neoplasm and rapid AD progression, respectively). 餘顧鏇積淵範窪衊繭網 (鹽鏇廠餘觸鑰夢蓋鹽鑰 ) | - | 2015-01-01 |